

1. [India needs strong IPR policy to boost 'Make in India' campaign: Experts](#)

– Business Standard

Although Prime Minister Narendra Modi has been harping on India's support for intellectual property rights (IPR), the country's ranking on the global platform has remained rather stagnant.

Experts feel that things would only fall in place once the country finalises a strong IPR policy.

The national IPR policy, drafted by the Department of Industrial Policy & Promotion, is yet to get an approval from the union cabinet, although it is likely to get this soon.

2. [Tech-savvy entrepreneurs, can you put India on the global innovation map?](#)

– Mint

“India can't make it to the top ranks among innovative nations.” This was the pessimistic forecast I heard from a middle-aged entrepreneur who is setting up a high-technology manufacturing company in India at a Confederation of Indian Industry (CII) innovation conference last week. In the past, when I expressed similar sentiments, this triggered heated discussions about the definition of innovation. Many people have also asked me how can India not be considered innovative when our people come up with so many creative solutions to the myriad problems they face?

3. [India's pharma industry may touch \\$55 billion by 2020: Assocham and TechSci report](#) - Economic Times

Country's pharma sector is likely to grow over three-fold to hit USD 55 billion in the next five years, even as the exports from the sector may slow down to grow at a CAGR of 7.98 per cent owing to stricter regulations in markets such as the US, Russia and Africa, says a report.

Consolidation of pharmacy players in North America has resulted in the presence of leading firms that hold better bargaining power, it added.

Also appeared in [The Hindu](#)

4. [The Price Keeps Falling For a Superstar Gilead Drug in India](#) – Bloomberg

Drugmakers have made the village of Lande Rode one of the theaters in a battle to grab market share for sofosbuvir, a miracle cure that Gilead Sciences Inc. sells in the U.S. as Sovaldi at a retail price of \$1,000 a pill. Gilead licensed 11 Indian companies to make generic versions, and they sealed marketing deals with others. Competition has been so fierce it's driven down the cost and spurred thousands to be tested.

1. [India needs strong IPR policy to boost 'Make in India' campaign: Experts](#) – Business Standard

2. [Tech-savvy entrepreneurs, can you put India on the global innovation map?](#) – Mint

3. [India's pharma industry may touch \\$55 billion by 2020: Assocham and TechSci report](#) - Economic Times

4. [The Price Keeps Falling For a Superstar Gilead Drug in India](#) – Bloomberg

5. [Bring amendment to two important acts to logical conclusion: Parliamentary panel](#) – Economic Times

The companies sponsor screening drives, hand out free test kits to hospitals and offer bulk discounts to entire villages. Sofosbuvir was cheap by most any standard when it hit the market in Punjab at \$10 in March. Then the cost kept dropping, to as low as \$4.29, and doctors predict it will continue to fall.

5. [Bring amendment to two important acts to logical conclusion: Parliamentary panel](#) – Economic Times

A parliamentary panel has expressed concern over the delay of amending two crucial legislations and asked the AYUSH Ministry to "vigorously" pursue the matter within a given time frame.

"The Committee notes that there has been a recurring delay in amending the Drugs and Magic Remedies (Objectionable Advertisements) Act 1954 and the Drugs and Cosmetics Rules 1945.

"Though the process of amending the said Acts and Rules has been set in motion, its logical culmination is still a distance away. The committee would like the Ministry to vigorously pursue the matter of amending the said Act and Rules within a given time frame," the Ram Gopal Yadav-led committee said.